Drugmakers Fight Over Lucrative Pneumonia Vaccines

France Nouvelles Nouvelles

Drugmakers Fight Over Lucrative Pneumonia Vaccines
France Dernières Nouvelles,France Actualités
  • 📰 WSJhealth
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 53%

Rival drugmakers want to upend Pfizer’s dominance of the $7 billion worldwide market for pneumonia vaccines

Rival drugmakers are seeking to upend Pfizer Inc.’s dominance of the $7 billion worldwide market for pneumonia vaccines, launching what is shaping up to be one of the industry’s fiercest battles.

Merck & Co. has already introduced a new competitor to Pfizer’s Prevnar vaccine franchise, while GSK PLC and Vaxcyte Inc. are among companies developing shots that aim to win sales by protecting against even more strains of the pneumonia virus.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

WSJhealth /  🏆 413. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia VaccinesPfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia VaccinesThe growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.
Lire la suite »

Key earnings reports, market recap, economic reports reviewed and more: Monday's 5 things to knowKey earnings reports, market recap, economic reports reviewed and more: Monday's 5 things to knowTraders will be watching this week as Fox Corp. and News Corp. will release third-quarter earnings on Tuesday along with health company earnings including CVS Health and Pfizer.
Lire la suite »

U.S. CDC director experiences COVID rebound after taking Pfizer's PaxlovidU.S. CDC director experiences COVID rebound after taking Pfizer's PaxlovidThe director of the U.S. Centers for Disease Control and Prevention (CDC), Rochelle Walensky, experienced a COVID-19 rebound after completing a course of Pfizer Inc's COVID-19 pill, the agency said on Monday.
Lire la suite »

Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia VaccinesPfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia VaccinesThe growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.
Lire la suite »

Actually, You Do Need a Stock PotActually, You Do Need a Stock PotRegular pots are fine if you don't mind small batches of sauce and boil overs.
Lire la suite »

How Does Cellular Immunity Work?How Does Cellular Immunity Work?Vaccines or infections generate antibodies and cellular immunity, or B and T cells. Both are essential to the COVID vaccine and booster response. MedTwitter
Lire la suite »



Render Time: 2025-03-12 15:47:00